26.68 USD
+0.39 (+1.48%)
26.68 USD
0 (0%)
Taking everything into account, PCRX scores 6 out of 10 in our fundamental rating. PCRX was compared to 191 industry peers in the Pharmaceuticals industry. While PCRX has a great profitability rating, there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
PCRX had positive earnings in the past year.
In the past year PCRX had a positive cash flow from operations.
Of the past 5 years PCRX 4 years were profitable.
Each year in the past 5 years PCRX had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 1.65%, PCRX belongs to the best of the industry, outperforming 81.15% of the companies in the same industry.
PCRX has a Return On Equity of 2.95%. This is amongst the best in the industry. PCRX outperforms 82.20% of its industry peers.
PCRX has a Return On Invested Capital of 3.63%. This is amongst the best in the industry. PCRX outperforms 81.68% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
The Profit Margin of PCRX (2.99%) is better than 79.06% of its industry peers.
PCRX has a better Operating Margin (8.88%) than 81.15% of its industry peers.
PCRX's Operating Margin has improved in the last couple of years.
PCRX's Gross Margin of 79.17% is amongst the best of the industry. PCRX outperforms 84.29% of its industry peers.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
Compared to 1 year ago, PCRX has less shares outstanding
Compared to 5 years ago, PCRX has more shares outstanding
PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.11 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
PCRX has a Altman-Z score (2.11) which is comparable to the rest of the industry.
The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of PCRX (3.03) is better than 90.05% of its industry peers.
A Debt/Equity ratio of 0.52 indicates that PCRX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.52, PCRX is doing worse than 62.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2.11 |
ROIC/WACC0.45
WACC8.13%
2.3 Liquidity
A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
PCRX has a Current ratio of 5.26. This is in the better half of the industry: PCRX outperforms 65.44% of its industry peers.
PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.78, PCRX is in line with its industry, outperforming 59.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
PCRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.96% yearly.
Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -16.85% in the last year.
PCRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.73% yearly.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
PCRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.17% yearly.
The Revenue is expected to grow by 6.09% on average over the next years.
EPS Next Y-6%
EPS Next 2Y3.5%
EPS Next 3Y6.17%
EPS Next 5Y7.17%
Revenue Next Year4.36%
Revenue Next 2Y6.92%
Revenue Next 3Y7.35%
Revenue Next 5Y6.09%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 8.98 indicates a reasonable valuation of PCRX.
Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 92.15% of the companies listed in the same industry.
PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.55.
The Price/Forward Earnings ratio is 7.76, which indicates a rather cheap valuation of PCRX.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaply inside the industry as 91.10% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (23.78), we can say PCRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.98 | ||
| Fwd PE | 7.76 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 91.10% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 91.62% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.24 | ||
| EV/EBITDA | 7.52 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.64
EPS Next 2Y3.5%
EPS Next 3Y6.17%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
26.68
+0.39 (+1.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners114.07%
Inst Owner Change-5.56%
Ins Owners0.79%
Ins Owner Change-1.27%
Market Cap1.15B
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.77 (15.33%)
Short Float %17.24%
Short Ratio11.78
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)-19.34%
PT rev (3m)-19.34%
EPS NQ rev (1m)2.44%
EPS NQ rev (3m)5.08%
EPS NY rev (1m)3.01%
EPS NY rev (3m)4.39%
Revenue NQ rev (1m)-1.53%
Revenue NQ rev (3m)-2.09%
Revenue NY rev (1m)-0.96%
Revenue NY rev (3m)-1.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.98 | ||
| Fwd PE | 7.76 | ||
| P/S | 1.6 | ||
| P/FCF | 9.24 | ||
| P/OCF | 8.12 | ||
| P/B | 1.58 | ||
| P/tB | 3.54 | ||
| EV/EBITDA | 7.52 |
EPS(TTM)2.97
EY11.13%
EPS(NY)3.44
Fwd EY12.89%
FCF(TTM)2.89
FCFY10.82%
OCF(TTM)3.29
OCFY12.32%
SpS16.66
BVpS16.9
TBVpS7.54
PEG (NY)N/A
PEG (5Y)0.64
Graham Number33.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 2.11 |
F-Score7
WACC8.13%
ROIC/WACC0.45
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-6%
EPS Next 2Y3.5%
EPS Next 3Y6.17%
EPS Next 5Y7.17%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.36%
Revenue Next 2Y6.92%
Revenue Next 3Y7.35%
Revenue Next 5Y6.09%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.36%
EBIT Next 3Y6.78%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What are the PE and PB ratios of PACIRA BIOSCIENCES INC (PCRX) stock?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.98 and the Price/Book (PB) ratio is 1.58.
What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?
The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 6 / 10.